BiotechTube

ASP2998 + Pembrolizumab + Enfortumab Vedotin + Carboplatin

Phase 1/2Recruiting
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Locally Advanced or Metastatic Malignant Solid Tumors

Conditions

Locally Advanced or Metastatic Malignant Solid Tumors

Trial Timeline

Feb 5, 2026 → Jun 30, 2029

NCT ID
NCT07287995

About ASP2998 + Pembrolizumab + Enfortumab Vedotin + Carboplatin

ASP2998 + Pembrolizumab + Enfortumab Vedotin + Carboplatin is a phase 1/2 stage product being developed by Astellas Pharma for Locally Advanced or Metastatic Malignant Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07287995. Target conditions include Locally Advanced or Metastatic Malignant Solid Tumors.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT07287995Phase 1/2Recruiting

Competing Products

20 competing products in Locally Advanced or Metastatic Malignant Solid Tumors

See all competitors
ProductCompanyStageHype Score
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
Tadalafil + GemcitabineEli LillyPhase 1
33
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
33
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
77
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
77
T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + RilvegostomigDaiichi SankyoPhase 1
33
zolbetuximabAstellas PharmaPre-clinical
23
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
52
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
77
enfortumab vedotin (EV)Astellas PharmaPre-clinical
23
zolbetuximabAstellas PharmaPre-clinical
23
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
77
ASP3082Astellas PharmaPhase 2
52
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
77
ASP1948Astellas PharmaPhase 1
33
Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )Sun PharmaceuticalPhase 2
52
Camrelizumab and Apatinib Plus GPSun PharmaceuticalPhase 1/2
41

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85